ProCE Banner Activity


Precision Therapeutic Strategies in Gynecologic Oncology: Updates & Considerations for Managed Care Professionals


On-demand webcast of expert faculty presentation and case discussion on key updates in gynecologic oncology and precision medicine to individualize care, in particular for managed care professionals.

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: May 09, 2024

Expiration: November 30, 2024



Laura R. Bobolts

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
Pompano Beach, Florida 

Kelly Romo

Kelly Romo, PharmD, BCOP

Manager of Oncology Drug Management
Blue Cross Blue Shield of Michigan
Detroit, Michigan

Provided by

Provided by ProCE, LLC in partnership with Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca and GlaxoSmithKline.




Clinical Care Options, LLC

ProCE Banner

Target Audience

The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists who care for patients with ovarian, endometrial, and cervical cancers, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice and managed care.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with gynecologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the cost-effectiveness and therapeutic implications of therapies for patients with ovarian cancer, considering factors such as BRCA mutations or other homologous recombination repair deficiencies, to guide decisions in both frontline and relapsed settings

  • Assess the value proposition and patient-specific benefits of immune ICI-based therapies as first-line regimens for endometrial and cervical cancers, factoring in tumor attributes and patient demographics

  • Strategize a biomarker testing framework that optimally positions ADCs in treatment plans for patients with gynecologic malignancies

  • Determine patient cohorts with gynecologic cancers at a heightened risk of adverse outcomes, ensuring they have access to comprehensive educational resources and support from diagnosis through treatment phases, in line with managed care principles


ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Laura R. Bobolts, PharmD, BCOP

SVP, Clinical Strategy and Growth
Pompano Beach, Florida 

Laura R. Bobolts, PharmD, BCOP, has no relevant financial relationships to disclose.

Kelly Romo, PharmD, BCOP

Manager of Oncology Drug Management
Blue Cross Blue Shield of Michigan
Detroit, Michigan

Kelly Romo, PharmD, BCOP, has no relevant financial relationships to disclose.

The planners and content peer reviewers from ProCE, LLC and Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 09, 2024, through November 30, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-24-006-H01-P has been assigned to this home study application-based activity. This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of the evaluation and the post-test with a score of 65 or higher are required to receive CE credit. No partial credit will be given. Statements of completion will be issued online at, and proof of completion will be posted in NABP CPE Monitor profiles.